Explore
Trendline
Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq
Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq
Read More
Trendline
Bruker Corporation Launches New NMR Products to Enhance Research and Automation
Bruker Corporation Launches New NMR Products to Enhance Research and Automation
Read More
Trendline
Promega Corporation Expands Forensic Offerings with NimaGen Distribution Agreement
Promega Corporation Expands Forensic Offerings with NimaGen Distribution Agreement
Read More
Trendline
Astellas Pharma to Close Universal Cells' Seattle Office, Affecting 50 Employees
Astellas Pharma to Close Universal Cells' Seattle Office, Affecting 50 Employees
Read More
Rapid Read
Stanford Health Care and Alameda Health System Partner to Enhance St. Rose Hospital Services
Stanford Health Care and Alameda Health System have announced a partnership to expand specialized care at St. Rose Hospital in Hayward, California. This collaboration aims to reinforce the hospital's stability and ensure continued access to high-quality care for the local community. The partnership includes the establishment of the St. Rose Hospital Community Fund to support hospital services and address broader health access needs. Additionally, Stanford Health Care physicians will provide care at the hospital's skilled nursing facility, and plans are in place to develop a community-based inpatient medical psychiatric unit.
Read More
Trendline
Invivoscribe Launches PrepQuant System to Enhance Molecular Testing Consistency
Invivoscribe Launches PrepQuant System to Enhance Molecular Testing Consistency
Read More
Trendline
Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment
Vir Biotechnology Begins Phase 1 Trial for Prostate Cancer Treatment
Read More
Trendline
FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Enhancing Antibody Discovery
FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Enhancing Antibody Discovery
Read More
Trendline
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial
Read More
Trendline
FairJourney Bio Launches Cryo-EM Facility in San Diego to Enhance Antibody Discovery
FairJourney Bio Launches Cryo-EM Facility in San Diego to Enhance Antibody Discovery
Read More
Trendline
FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence
FairJourney Bio Launches Advanced Cryo-EM Facility in San Diego, Expanding U.S. Biotech Presence
Read More
Rapid Read
PRSS56 Gene Identified as Key Target for Myopia Treatment
Recent studies have highlighted the PRSS56 gene as a significant factor in the development of myopia, a condition characterized by excessive axial elongation of the eye. Research conducted by Wu et al. has identified two non-coding variants in PRSS56 that are associated with high myopia in affected individuals. These findings were derived from molecular genetic analyses of multigenerational pedigrees and supported by evidence from mouse models and in vitro systems. The study suggests that increased expression of PRSS56 may lead to axial elongation, making it a potential therapeutic target for myopia treatment. This discovery opens new avenues for developing treatments that could prevent or slow the progression of myopia, which is prevalent among young adults worldwide.
Read More
